Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,198.7
-15.0 (-0.47%)

 

  • STI Straits Times Index
    3,198.7
    -15.0 (-0.47%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,535.0
    0.8 (0.05%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    27,609.2
    -46.7 (-0.17%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    3,030.2
    54.8 (1.84%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    23,479.2
    78.5 (0.34%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    5,942.5
    13.7 (0.23%)
    Index delayed 10 minutes

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 1,239.6M
  • Value: 1,113.8M
  • Rise: 156
  • Fall: 146
  • Unch: 512

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
AusGroup^0.052-
IPS Securex0.072-
OEL0.029-
YZJ Shipbldg SGD1.040+0.020
ESR-REIT0.550+0.005
Tritech0.023-
SunMoonFood^0.048+0.003
Sino Grandness0.032+0.003
Sen Yue0.031+0.005
Singtel3.130-0.040

World Indices

World Indices
Name Last Change
Nasdaq 9,817.2 +84.4
HSI 27,609.2 -46.6
HSCEI 10,914.0 +5.4
Jakarta 5,942.5 +13.7
Nikkei 225 23,479.2 +78.5
SSE Comp 3,030.2 +54.8
Shanghai A 3,175.4 +57.4
Shanghai B 244.1 +4.7
KOSPI 2,195.5 -14.8

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

LIGAND PHARMACEUTICAL INC LIGAND PHARMACEUTICALS
Updated on 19 Feb 2020 (End of trading day)
Last (USD): 101.390 Change: +3.340 High: 103.090 Remarks: -
Change (%): +3.41 Low: 98.390
Open 98.950 Yesterday's Close 98.05
Buy Price - Sell Price -
Buy Volume (share) - Sell Volume (share) -
Cumulative Volume (share) 386,118 Cumulative Value
Click to show Stock Prices chart

Key Statistics

EPS (USD) a 8.16021 Trailing EPS (USD) e 35.83031 NAV (USD) b 43.6836
PE a 12.425 Trailing PE f 2.830 Price / NAV b 2.3210
Dividend (USD) d - Cash In Hand (USD) g 60.9146 Issued & Paid-up Shares c 17,563,400
Dividend Yield (%) d - Price / Cash In Hand g 1.664 Treasury Shares h -
Beta - 75 Daysi 1.075 R-Squared - 75 Days(%)i 11.63 Market Cap (M) 1,780.753
Beta - 500 Daysi 0.104 R-Squared - 500 Days (%)i 0.21 Enterprise Value (M) 1,359.815
Piotroski F Score 8 Exchange Code LGND Par Value ( $ ) n.a.
52 Weeks Volatility (%) 37.50 Free Float (%) 96.6
Sector & Industry Health Technology - Biotechnology
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. Updated on 13 Nov 2019.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand. Updated on 13 Jul 2015.
  9. Beta and R-Squared are calculated in relation to the market index using the historical daily closing values of the stock and index as data points.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference LIGAND PHARMACEUTICAL INC NASDAQ 1,780.753 12.425 2.830 2.3210 -
Industry Biotechnology NASDAQ 2,496.112 317.697 198.316 6.0367 0.728
Local Peer AMGEN INC NASDAQ 131,503.369 15.666 16.769 13.5949 2.528
Local Peer GILEAD SCIENCES INC NASDAQ 85,265.100 15.631 15.831 3.7645 3.428
Local Peer VERTEX PHARMACEUTICAL NASDAQ 64,241.673 30.644 54.590 10.5569 -
Local Peer BIOGEN INC NASDAQ 59,362.787 13.398 10.081 4.4489 -
Local Peer ILLUMINA INC NASDAQ 44,570.400 53.959 44.481 9.6619 -
Local Peer REGENERON PHARMACEUTICALS INC NASDAQ 44,097.104 18.040 20.842 3.9764 -
Local Peer ALEXION PHARMACEUTICAL INC NASDAQ 22,850.797 294.465 9.504 2.0273 -
Local Peer SEATTLE GENETICS INC NASDAQ 20,652.251 - - 11.0070 -
Local Peer INCYTE CORPORATION NASDAQ 17,866.678 163.176 39.979 6.8760 -
Local Peer GALAPAGOS NV SPON ADR REPR 1 ORD SHS NASDAQ 17,245.396 - 55.566 6.2394 -
Local Peer BIOMARIN PHARMACEUTICAL NASDAQ 16,142.899 - - 5.2507 -
Local Peer EXACT SCIENCES CORP NASDAQ 15,094.225 - - 6.5970 -
Other Local Peers ALNYLAM PHARMACEUTICALS INC (NASDAQ), BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS (NASDAQ), NEUROCRINE BIOSCIENCES INC (NASDAQ), SAREPTA THERAPEUTICS INC (NASDAQ), 10X GENOMICS INC (NASDAQ), IONIS PHARMACEUTICALS INC (NASDAQ), BIO-TECHNE CORP (NASDAQ), BIONTECH SE SPON ADS EACH REP 1 ORD SHS (NASDAQ), ACADIA PHARMACEUTICALS INC (NASDAQ), ASCENDIS PHARMA A/S SPON ADR EACH REP 1 ORD SHS (NASDAQ), MODERNA INC (NASDAQ), EXELIXIS INC (NASDAQ), ACCELERON PHARMA (NASDAQ), ZAI LAB LIMITED ADS EACH REP 1 ORD SHS (NASDAQ), CHINA BIOLOGIC PRODUCTS HLDGS INC (NASDAQ), BLUEBIRD BIO INC (NASDAQ), GLOBAL BLOOD THERAPEUTICS INC (NASDAQ), MIRATI THERAPEUTICS INC (NASDAQ), ARROWHEAD PHARMACEUTICALS INC (NASDAQ), FIBROGEN INC (NASDAQ), MORPHOSYS SPON ADS EACH REP 0.25 ORD SHS (NASDAQ), MOMENTA PHARMACEUTICALS INC (NASDAQ), IMMUNOMEDICS INC (NASDAQ), PTC THERAPEUTICS INC (NASDAQ), BLUEPRINT MEDICINES CORP (NASDAQ), AGIOS PHARMACEUTICALS INC (NASDAQ), ULTRAGENYX PHARMACEUTICAL INC (NASDAQ), CRISPR THERAPEUTICS AG (NASDAQ), IOVANCE BIOTHERAPEUTICS INC (NASDAQ), ALLOGENE THERAPEUTICS INC (NASDAQ), ALKERMES PLC (NASDAQ), CHEMOCENTRYX INC (NASDAQ), HALOZYME THERAPEUTICS INC (NASDAQ), DECIPHERA PHARMACEUTICALS INC (NASDAQ), INSMED INC (NASDAQ), UNIQURE N.V. (NASDAQ), AMICUS THERAPEUTICS INC (NASDAQ), DENALI THERAPEUTICS INC (NASDAQ), ARENA PHARMACEUTICALS INC (NASDAQ), KODIAK SCIENCES INC (NASDAQ), VIELA BIO INC (NASDAQ), ALECTOR INC (NASDAQ), EPIZYME INC (NASDAQ), FATE THERAPEUTICS (NASDAQ), AURINIA PHARMACEUTICALS INC (NASDAQ), XENCOR INC (NASDAQ), REGENXBIO INC (NASDAQ), ARVINAS INC (NASDAQ), HERON THERAPEUTICS INC (NASDAQ), EIDOS THERAPEUTICS INC (NASDAQ), ESPERION THERAPEUTICS INC (NASDAQ), VIR BIOTECHNOLOGY INC (NASDAQ), AIMMUNE THERAPEUTICS INC (NASDAQ), TG THERAPEUTICS INC (NASDAQ), CORTEXYME INC (NASDAQ), COHERUS BIOSCIENCES INC (NASDAQ), INTRA-CELLUAR THERAPIES INC (NASDAQ), MYRIAD GENETICS INC (NASDAQ), DICERNA PHARMACEUTICALS INC. (NASDAQ), BEAM THERAPEUTICS INC (NASDAQ), EDITAS MEDICINE INC (NASDAQ), NEXTCURE INC (NASDAQ), ROCKET PHARMACEUTICALS INC (NASDAQ), VERACYTE INC (NASDAQ), BLACK DIAMOND THERAPEUTICS INC (NASDAQ), NANOSTRING TECHNOLOGIES INC (NASDAQ), ADVERUM BIOTECHNOLOGIES INC (NASDAQ), AVITA MEDICAL LTD SPON ADS EACH REP 20 ORD SHS (NASDAQ), AKEBIA THERAPEUTICS INC (NASDAQ), NGM BIOPHARMACEUTICALS INC (NASDAQ), LUMINEX CORP(DEL) (NASDAQ), ENANTA PHARMACEUTICALS INC (NASDAQ), DERMIRA INC (NASDAQ), KARYOPHARM THERAPEUTICS INC (NASDAQ), TWIST BIOSCIENCE CORPORATION (NASDAQ), MESOBLAST LTD SPON ADR EACH REP 5 SHS (NASDAQ), DBV TECHNOLOGIES SPON ADR EACH REPR 0.5 ORD (NASDAQ), IMMUNOGEN INC (NASDAQ), CYTOKINETICS INC (NASDAQ), RADIUS HEALTH INC (NASDAQ), STOKE THERAPEUTICS INC (NASDAQ), APPLIED THERAPEUTICS INC (NASDAQ), SANGAMO THERAPEUTICS INC (NASDAQ), HOMOLOGY MEDICINES INC (NASDAQ), AVROBIO INC (NASDAQ), RHYTHM PHARMACEUTICALS INC (NASDAQ), CARA THERAPEUTICS INC (NASDAQ), ATARA BIOTHERAPEUTICS INC (NASDAQ), CELLECTIS ADS EACH REPR 1 ORD SPON (NASDAQ), RAPT THERAPEUTICS INC (NASDAQ), CLOVIS ONCOLOGY INC (NASDAQ), PRECIGEN INC (NASDAQ), BIOXCEL THERAPEUTICS INC (NASDAQ), FREQUENCY THERAPEUTICS INC (NASDAQ), RETROPHIN INC (NASDAQ), OMEROS CORP (NASDAQ), VANDA PHARMACE INC (NASDAQ), ARDELYX INC (NASDAQ), GENFIT SPON ADS EACH REP 1 ORD SHS (NASDAQ), PACIFIC BIOSCIENCES CALIFORNIA INC (NASDAQ), INTELLIA THERAPEUTICS INC (NASDAQ), MOLECULAR TEMPLATES INC (NASDAQ), RUBIUS THERAPEUTICS INC (NASDAQ), ZIOPHARM ONCOLOGY INC (NASDAQ), APTOSE BIOSCIENCES INC (NASDAQ), MEIRAGTX HOLDINGS PLC (NASDAQ), UROGEN PHARMA LTD (NASDAQ), REPLIMUNE GROUP INC (NASDAQ), INNATE PHARMA SPON ADS EACH REP 1 ORD SHS (NASDAQ), FLEXION THERAPEUTICS INC (NASDAQ), XBIOTECH INC (NASDAQ), COMPUGEN (NASDAQ), AGENUS INC (NASDAQ), NANTKWEST INC (NASDAQ), PREVAIL THERAPEUTICS INC (NASDAQ), MERUS B V (NASDAQ), BELLUS HEALTH INC (NASDAQ), KURA ONCOLOGY INC (NASDAQ), AUTOLUS THERAPEUTICS PLC SPON ADS EA REP 1 ORD SHS (NASDAQ), PUMA BIOTECHNOLOGY INC (NASDAQ), MACROGENICS INC (NASDAQ), MAGENTA THERAPEUTICS INC (NASDAQ), ADAPTIMMUNE THERAPEUTICS PLC ADS EACH REPR 6 SHS (SPONS) (NASDAQ), VIKING THERAPEUTICS INC (NASDAQ), XENON PHARMACEUTICALS INC (NASDAQ), TRANSLATE BIO INC (NASDAQ), VOYAGER THERAPEUTICS INC (NASDAQ), PROTHENA CORP PLC (NASDAQ), CUE BIOPHARMA INC (NASDAQ), SINOVAC BIOTECH LTD (NASDAQ), SORRENTO THERAPEUTICS INC (NASDAQ), MERSANA THERAPEUTICS INC (NASDAQ), BIOCRYST PHARMACEUTICALS INC (NASDAQ), PROQR THERAPEUTICS N V (NASDAQ), MORPHIC HOLDING INC (NASDAQ), SCHOLAR ROCK HOLDING CORPORATION (NASDAQ), ANAPTYSBIO INC (NASDAQ), CALITHERA BIOSCIENCES INC (NASDAQ), PRECISION BIOSCIENCES INC (NASDAQ), DYNAVAX TECHNOLOGIES CORP (NASDAQ), PDL BIOPHARMA INC (NASDAQ), CORBUS PHARMACEUTICALS HOLDINGS IN (NASDAQ), AVID BIOSERVICES INC (NASDAQ), CABALETTA BIO INC (NASDAQ), PROGENICS PHARMACEUTICALS INC (NASDAQ), SELECTA BIOSCIENCES INC (NASDAQ), RIGEL PHARMACEUTICALS INC (NASDAQ), RECRO PHARMA INC (NASDAQ), HARPOON THERAPEUTICS INC (NASDAQ), STEMLINE THERAPEUTICS INC (NASDAQ), NEUROINSIGHTS NEUROTECH (NASDAQ), MERIDIAN BIOSCIENCE INC COM (NASDAQ), CONCERT PHARMACEUTICALS INC (NASDAQ), CYTOMX THERAPEUTICS INC (NASDAQ), PERSONALIS INC (NASDAQ), CELLULAR BIOMEDICINE GROUP INC (NASDAQ), EVOFEM BIOSCIENCES INC (NASDAQ), ADMA BIOLOGICS INC (NASDAQ), IVERIC BIO INC (NASDAQ), SYNDAX PHARMACEUTICALS INC (NASDAQ), ANAVEX LIFE SCIENCES CORPORATION (NASDAQ), LEXICON PHARMACEUTICALS INC (NASDAQ), SYROS PHARMACEUTICALS INC (NASDAQ), NEUROBO PHARMACEUTICALS INC (NASDAQ), SPECTRUM PHARMACEUTICALS INC (NASDAQ), WAVE LIFE SCIENCES LTD (NASDAQ), MANNKIND CORPORATION (NASDAQ), EIGER BIOPHARMACEUTICALS INC (NASDAQ), ADURO BIOTECH INC (NASDAQ), BICYCLE THERAPEUTICS PLC SPON ADS EACH REP 1 ORD SHS (NASDAQ), TRILLIUM THERAPEUTICS INC (NASDAQ), UNITY BIOTECHNOLOGY INC (NASDAQ), KAMADA (NASDAQ), VBI VACCINES INC CDA (NASDAQ), GERON CORP (NASDAQ), NOVAVAX INC (NASDAQ), MEDICINOVA INC (NASDAQ), SERES THERAPEUTICS (NASDAQ), BIOFRONTERA AG SPON ADS EACH REP TWO ORD SHS (NASDAQ), XOMA CORP (NASDAQ), PROTAGONIST THERAPEUTICS INC (NASDAQ), LA JOLLA PHARMACEUTICAL CO (NASDAQ), IMV INC (NASDAQ), LIMINAL BIOSCIENCES INC (NASDAQ), AFFIMED N V (NASDAQ), CASI PHARMACEUTICALS INC (NASDAQ), PIERIS PHARMACEUTICALS INC (NASDAQ), ARBUTUS BIOPHARMA CORP (NASDAQ), KEZAR LIFE SCIENCES INC (NASDAQ), ATHERSYS INC (NASDAQ), JOUNCE THERAPEUTICS INC (NASDAQ), FORTRESS BIOTECH INC (NASDAQ), CHIASMA INC (NASDAQ), FIVE PRIME THERAPEUTICS (NASDAQ), STRONGBRIDGE BIOPHARMA PLC (NASDAQ), TAIWAN LIPOSOME COMPANY LTD SPON ADS EACH REP 2 ORD SHS (NASDAQ), GLYCOMIMETICS INC (NASDAQ), X4 PHARMACEUTICALS INC (NASDAQ), VTV THERAPEUTICS INC (NASDAQ), CONTRAFECT CORP (NASDAQ), SIERRA ONCOLOGY INC (NASDAQ), NUCANA PLC SPON ADR EACH REP 1 ORD SHS (NASDAQ), NEPTUNE WELLNESS SOLUTIONS INC (NASDAQ), FENNEC PHARMACEUTICALS INC (NASDAQ), VERASTEM INC (NASDAQ), DYADIC INTERNATIONAL INC (NASDAQ), ELOXX PHARMACEUTICALS INC (NASDAQ), SOLID BIOSCIENCES INC (NASDAQ), NABRIVA THERAPEUTICS PLC (NASDAQ), CELYAD ADS EACH REPR 1 ORD (NASDAQ), ALDEYRA THERAPEUTICS (NASDAQ), GALECTIN THERAPEUTICS INC (NASDAQ), APPLIED GENETIC TECHNOLOGIES CORP (NASDAQ), BRAINSTROM CELL THERAPEUTICS (NASDAQ), ARAVIVE INC (NASDAQ), AVALON GLOBOCARE CORP (NASDAQ), ERYTECH PHARMA SPON ADR EACH REPR 1 ORD (NASDAQ), INFLARX N V (NASDAQ), CYMABAY THERAPEUTICS INC (NASDAQ), MONOPAR THERAPEUTICS INC (NASDAQ), PARATEK PHARMACEUTICALS INC (NASDAQ), EDAP TMS S.A. SPON ADR EACH REPR 1 ORD SHARE (NASDAQ), OTONOMY INC (NASDAQ), SAVARA INC (NASDAQ), IMMUTEP LTD SPON ADS EACH REP 10 ORD SHS (NASDAQ), CATALYST BIOSCIENCES INC (NASDAQ), CIDARA THERAPEUTICS INC (NASDAQ), AXCELLA HEALTH INC (NASDAQ), CHIMERIX INC (NASDAQ), HARVARD BIOSCIENCE INC (NASDAQ), AXOVANT GENE THERAPIES LTD (NASDAQ), CATABASIS PHARMACEUTICALS INC (NASDAQ), SUMMIT THERAPEUTICS PLC ADS EACH REPR 5 ORD (NASDAQ), SURFACE ONCOLOGY INC (NASDAQ), VACCINEX INC (NASDAQ), ORGENESIS INC (NASDAQ), SESEN BIO INC (NASDAQ), PROTEOSTASIS THERAPEUTICS INC (NASDAQ), EQUILLIUM INC (NASDAQ), SUNESIS PHARMACEUTICALS INC (NASDAQ), AVEO PHARMACEUTICALS INC (NASDAQ), CHAMPIONS ONCOLOGY INC (NASDAQ), ACORDA THERAPEUTICS INC (NASDAQ), SYNLOGIC INC (NASDAQ), ASLAN PHARMACEUTICALS LIMITED ADS EACH REP 5 ORD SHS (NASDAQ), VERMILLION INC (NASDAQ), ANPAC BIO MEDICAL SCIENCE CO LTD SPON ADS EACH REPR 1 ORD SHS CLASS A (NASDAQ), PLURISTEM THERAPEUTICS INC (NASDAQ), INFINITY PHARMACEUTICALS INC (NASDAQ), COHBAR INC (NASDAQ), DIAMEDICA THERAPEUTICS INC (NASDAQ), STEALTH BIOTHERAPEUTICS CORP SPON ADS EACH REP 12 ORD SHS (NASDAQ), CO DIAGNOSTICS INC (NASDAQ), ONCONOVA THERAPEUTICS INC (NASDAQ), ANIXA BIOSCIENCES INC (NASDAQ), TREVENA INC (NASDAQ), LEAP THERAPEUTICS INC (NASDAQ), SOLIGENIX INC (NASDAQ), ENTASIS THERAPEUTICS HLDGS INC (NASDAQ), MICROBOT MEDICAL INC (NASDAQ), ADVAXIS INC (NASDAQ), ALPINE IMMUNE SCIENCES INC (NASDAQ), ONCOLYTICS BIOTECH INC (NASDAQ), GENOCEA BIOSCIENCES INC (NASDAQ), NEWLINK GENETICS CORP (NASDAQ), TIZIANA LIFE SCIENCES PLC SPON ADS EACH REPR 10 ORD SHS (NASDAQ), AQUABOUNTY TECHNOLOGIES INC (NASDAQ), INMUNE BIO INC (NASDAQ), RESTORBIO INC (NASDAQ), OPIANT PHARMACEUTICALS INC (NASDAQ), FORWARD PHARMA AS SPON ADS EACH REP 14 ORD SHS (NASDAQ), BELLICUM PHARMACEUTICALS (NASDAQ), VASCULAR BIOGENICS LTD (NASDAQ), VAXART INC (NASDAQ), CURIS INC (NASDAQ), T2 BIOSYSTEMS INC (NASDAQ), ZAFGEN INC (NASDAQ), IDERA PHARMACEUTICALS INC (NASDAQ), ITERUM THERAPEUTICS PLC (NASDAQ), ORGANOVO HLDGS INC (NASDAQ), NEON THERAPEUTICS INC (NASDAQ), OUTLOOK THERAPEUTICS INC (NASDAQ), MERRIMACK PHARMACEUTICALS INC (NASDAQ), MEREO BIOPHARMA GROUP PLC SPON ADS EACH REP 5 ORD SHS (NASDAQ), MIRAGEN THERAPEUTICS INC (NASDAQ), EVOGENE LTD (NASDAQ), SEELOS THERAPEUTICS INC (NASDAQ), ATYR PHARMA INC (NASDAQ), HTG MOLECULAR DIAGNOSTICS INC (NASDAQ), VISTAGEN THERAPEUTICS INC (NASDAQ), PULMATRIX INCORPORATED (NASDAQ), INNOVATE BIOPHARMACEUTICALS INC (NASDAQ), ALIMERA SCIENCES INC (NASDAQ), BIOCARDIA INC (NASDAQ), KAZIA THERAPEUTICS LIMITED SPON ADR EACH REP 10 ORD SHS (NASDAQ), OCUGEN INC (NASDAQ), BIONANO GENOMICS INC (NASDAQ), AETERNA ZENTARIS INC (NASDAQ), AZURRX BIOPHARMA INC (NASDAQ), SOPHIRIS BIO INC (NASDAQ), CELLECTAR BIOSCIENCES INC (NASDAQ), CLEVELAND BIOLABS INC (NASDAQ), UNUM THERAPEUTICS INC (NASDAQ), APTEVO THERAPEUTICS INC (NASDAQ), GENETIC TECHNOLOGIES SPON ADS EA REP 600 ORD SHS(R/S) (NASDAQ), BIO-PATH HOLDINGS INC (NASDAQ), TRACON PHARMACEUTICALS INC (NASDAQ), MIDATECH PHARMA PLC SPON ADS EACH REP 20 ORD SHS(R/S) (NASDAQ), CONATUS PHARMACEUTICALS INC (NASDAQ), HEAT BIOLOGICS INC (NASDAQ), SELLAS LIFE SCIENCES GROUP INC (NASDAQ), CORREVIO PHARMA CORP (NASDAQ), PRECIPIO INC (NASDAQ), DIFFUSION PHARMACEUTICALS INC (NASDAQ), CYCLACEL PHARMA IN (NASDAQ), REXAHN PHARMACEUTICALS INC (NASDAQ), TOCAGEN INC (NASDAQ), ENDRA LIFE SCIENCES INC (NASDAQ), ACHIEVE LIFE SCIENCE INC (NASDAQ), ALTERITY THERAPEUTICS LIMITED SPON ADS EA REPR 60 ORD SHS (NASDAQ), ANCHIANO THERAPEUTICS LTD SPON ADS EACH REP 5 ORD SHS (NASDAQ), BENITEC BIOPHARMA LTD SPON ADS EA REPR 200 ORD SHS(POST SPLIT) (NASDAQ), ARCA BIOPHARMA INC (NASDAQ), PLUS THERAPEUTICS INC (NASDAQ), SENECA BIOPHARMA INC (NASDAQ), CELLECT BIOTECHNOLOGY LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), XTL BIOPHARMACEUTICALS LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), XENETIC BIOSCIENCES INC (NASDAQ), SENESTECH INC (NASDAQ), CAPRICOR THERAPEUTICS INC (NASDAQ), AURIS MEDICAL HOLDING LTD (NASDAQ), SPHERIX INC (NASDAQ), INVIVO THERAPEUTICS HOLDING CORP (NASDAQ), THERAPIX BIOSCIENCES LTD SPON ADR EACH REP 40 ORD (POST SPLIT) (NASDAQ), PHIO PHARMACEUTICALS CORP (NASDAQ)
Global Peer CSL ASX 153,720.756 57.296 53.066 - 0.783
Global Peer AMGEN-T HKEx 589,807.000 8.965 9.598 7.8255 4.417
Global Peer AGILENT TECHNOLOGIES INC NYSE 26,524.049 83.937 24.766 - 0.715
Global Peer WUXI BIO HKEx 151,730.338 203.144 158.813 15.6188 -
Global Peer SINO BIOPHARM HKEx 143,596.803 13.401 13.909 4.2764 0.641
Global Peer BEIGENE HKEx 103,125.876 - - 10.2895 -
Global Peer GENSCRIPT BIO HKEx 32,978.597 198.325 - 9.2999 -
Global Peer Lonza SGX 5,937.453 6.613 6.613 0.6568 4.787
Global Peer 3SBIO HKEx 26,822.083 17.731 21.581 2.6436 -
Global Peer EMERGENT BIOSOLUTIONS INC NYSE 3,333.878 53.172 775.320 3.2211 -
Other Global Peers ALPHAMAB-B (HKEx), HAOHAI BIOTEC (HKEx), POLYNOVO LIMITED (ASX), FRONTAGE (HKEx), AVITA MEDICAL LTD (ASX), MYOVANT SCIENCES LTD (NYSE), MESOBLAST LTD (ASX), VIVA BIOTECH (HKEx), KADMON HLDGS INC (NYSE), ARCUS BIOSCIENCES INC (NYSE), ASCENTAGE-B (HKEx), ASCLETIS-B (HKEx), SINOMAB BIO-B (HKEx), ESSEX BIO-TECH (HKEx), NANOVIRICIDES INC (NYSE American), LEE'S PHARM (HKEx), PFENEX INC (NYSE American), TELIX PHARMACEUTIC (ASX), DPHARMA (Bursa), BBI LIFE SCI (HKEx), NEXT SCIENCE LTD (ASX), LINEAGE CELL THERAPEUTICS INC (NYSE American), NEUREN PHARMACEUTICALS LTD (ASX), CEL-SCI CORP (NYSE American), UNI-BIO GROUP (HKEx), MATINAS BIOPHARMA HOLDINGS INC (NYSE American), IMMUTEP LTD (ASX), ENZO BIOCHEM INC (NYSE), 22ND CENTURY GROUP INC (NYSE American), IMUGENE LIMITED (ASX), PALATIN TECHNOLOGIES INC (NYSE American), CYNATA THERAPEUTICS LTD (ASX), SYNTHETIC BIOLOGICS INC (NYSE American), BIOTRON (ASX), CT ENTERPRISE (HKEx), ARMATA PHARMACEUTICALS INC (NYSE American), INVEX THERAPEUTICS LTD NPV (ASX), BIOSINO BIO-TEC (HKEx), HOLISTA COLLTECH LIMITED (ASX), MEMPHASYS LTD (ASX), KAZIA THERAPEUTICS LIMITED (ASX), CCP TECHNOLOGIES LTD (ASX), REGENT PACIFIC (HKEx), IBIO INC (NYSE American), ORAGENICS INC (NYSE American), GENETIC TECHNOLOGIES (ASX), ANTEOTECH LIMITED (ASX), BIONOMICS LTD (ASX), ACTINOGEN MEDICAL LTD (ASX), ACTINIUM PHARMACEUTICALS INC (NYSE American), RHINOMED LIMITED (ASX), INDIA GLOBALIZATION CAPITAL INC (NYSE American), PRESCIENT THERAPEUTICS LIMITED (ASX), CONTANGO ASSET MANAGEMENT LIMITED (ASX), Suntar Eco-City^ (SGX), PATRYS LIMITED (ASX), REGENEUS LTD (ASX), ALTERITY THERAPEUTICS LIMITED (ASX), SIENNA CANCER DIAGNOSTICS LTD (ASX), HAO WEN HLDGS (HKEx), ADALTA LTD (ASX), NOVABAY PHARMACEUTICALS INC (NYSE American), AIM IMMUNOTECH INC (NYSE American), ANATARA LIFESCIENCES LTD (ASX), NEUROSCIENTIFIC BIOPHARMA LTD (ASX), BENITEC BIOPHARMA LTD (ASX), LIVING CELL TECHNOLOGIES (ASX), CAN FITE BIOPHARMA LTD SPON ADS EA REP 30 ORD SHS(POST REV SPL (NYSE American), AUSTRALIAN PRIMARY HEMP LTD (ASX), LEAF RESOURCES LTD (ASX), AMPLIA THERAPEUTICS LTD (ASX), AVECHO BIOTECHNOLOGY LTD (ASX), NANOLLOSE LTD (ASX), FACTOR THERAPEUTICS LIMITED (ASX), CRYOSITE (ASX)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days -+5.710
+5.97 %
10 Days -+8.910
+9.63 %
20 Days -+11.450
+12.73 %
Medium Term Return 3 Months --7.720
-7.08 %
6 Months -+5.490
+5.72 %
1 Year --15.790
-13.47 %
Long Term Return 2 Years --54.140
-34.81 %
3 Years --1.450
-1.41 %
5 Years -+45.570
+81.64 %
Annualised Return Annualised --
+12.68 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 84.450 - 130.500 Change From 1 Year Low +16.940 % Change From 1 Year Low (%) +20.06
Change From 1 Year High -29.110 % Change From 1 Year High (%) -22.31
2 Years Range 84.450 - 278.620 Change From 2 Years Low +16.940 % Change From 2 Years Low (%) +20.06
Change From 2 Years High -177.230 % Change From 2 Years High (%) -63.61
5 Years Range 54.920 - 278.620 Change From 5 Years Low +46.470 % Change From 5 Years Low (%) +84.61
Change From 5 Years High -177.230 % Change From 5 Years High (%) -63.61
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in San Diego, CA.

Historical Price Data

Date Open High Low Close Volume VWAP
19 Feb 2020 98.950 103.090 98.390 101.390 386,118 -
18 Feb 2020 97.230 98.370 96.500 98.050 207,987 -
14 Feb 2020 95.510 97.860 94.450 97.230 274,708 -
13 Feb 2020 94.870 96.520 94.060 95.680 302,977 -
12 Feb 2020 95.990 96.310 94.825 95.110 209,479 -
11 Feb 2020 96.450 96.925 94.710 94.760 302,790 -
10 Feb 2020 94.960 98.100 94.815 96.340 291,167 -
07 Feb 2020 94.900 99.370 92.500 95.270 640,210 -
06 Feb 2020 93.410 94.880 92.410 92.480 239,241 -
05 Feb 2020 91.350 93.790 91.060 92.190 374,776 -
04 Feb 2020 90.900 91.740 89.000 90.230 396,892 -
03 Feb 2020 89.710 91.450 89.280 89.510 374,240 -
31 Jan 2020 89.410 90.240 87.660 87.810 302,286 -
30 Jan 2020 88.500 89.980 87.710 89.810 217,892 -
29 Jan 2020 87.790 90.980 87.460 89.320 251,960 -
28 Jan 2020 87.270 88.600 85.940 88.020 276,843 -
27 Jan 2020 87.080 89.335 85.700 86.540 402,811 -
24 Jan 2020 90.330 90.590 87.850 88.540 342,495 -
23 Jan 2020 91.020 91.020 89.010 89.940 310,913 -
22 Jan 2020 89.860 92.717 89.530 91.200 353,200 -
21 Jan 2020 90.070 91.380 89.650 89.760 287,579 -
17 Jan 2020 93.150 93.230 89.620 90.390 315,022 -
Summary
Current 2 Weeks
(05 Feb 2020 to 19 Feb 2020)
91.350 103.090 91.060 101.390 3,229,453 -
Previous 2 Weeks
(22 Jan 2020 to 04 Feb 2020)
89.860 103.090 89.530 90.230 3,229,532 -
4 Weeks from
(20 Dec 2019 to 21 Jan 2020)
109.220 110.450 91.060 89.760 6,150,672 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.